Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Randomized, Controlled, Study Evaluating EVICEL Fibrin Sealant as an Adjunct to Hemostasis During, Abdominal, Retroperitoneal or Pelvic Surgery in Pediatric Patients

Next Previous
Search
Trial Profile

A Prospective, Randomized, Controlled, Study Evaluating EVICEL Fibrin Sealant as an Adjunct to Hemostasis During, Abdominal, Retroperitoneal or Pelvic Surgery in Pediatric Patients

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fibrinogen/thrombin (Primary) ; Oxidised cellulose
  • Indications Surgical blood loss
  • Focus Therapeutic Use
  • Sponsors Ethicon

    • Most Recent Events

    • 18 Nov 2019 Status changed from recruiting to completed.
    • 04 Aug 2019 This trial has been completed in Belgium (end date: 2019-05-17)
    • 12 Dec 2017 Planned End Date changed from 1 Feb 2018 to 30 Nov 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top